Volume 91 Issue 24 | p. 9 | News of The Week
Issue Date: June 17, 2013 | Web Date: June 14, 2013

AstraZeneca Buys Pearl Therapeutics

Pharma: Acquisition adds lung drug candidate to AstraZeneca’s pipelinerebuilding campaign
Department: Business
Keywords: pharmaceuticals, M&A, respiratory disease, COPD, biotech

In a bid to stay competitive in treating respiratory diseases, AstraZeneca is paying up to $1.15 billion for the privately held biotech firm Pearl Therapeutics. The acquisition is the latest in the British drugcompany’s piecemeal rebuilding of a new-product pipeline that has fallen apart inrecent years.

AstraZeneca brought in Pascal Soriot as CEO last October to find new products that could offset patent losses on top-selling drugs such as the . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society